TY  - JOUR
AU  - Krajnović, Milena M.
AU  - Jovanovic, Maja Perunicic
AU  - Mihaljevic, Biljana
AU  - Andelic, Bosko
AU  - Tarabar, Olivera
AU  - Knežević-Ušaj, Slavica
AU  - Krtolica-Žikić, Koviljka
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/192
AB  - In this study, methylation-specific polymerase chain reaction was used to investigate the potential prognostic significance of the methylation status of p15, p16, MGMT, and DAPK genes in 51 specimens of diffuse large B-cell lymphoma (DLBCL). Hypermethylation of p15 gene was significantly more prevalent in patients without relapse (p = 0.001) and there was a trend toward more frequent presence of p15 methylation in patients without death outcome within 5-year follow-up period (p = 0.086) Also, there was a trend toward accumulation of p15 methylation with favorable clinicopathological parameters including: age 60 years (p = 0.091), normal levels of lactate dehydrogenase (p = 0.090), Eastern Cooperative Oncology Group performance status LT 2 (p = 0.095), and low/intermediate low International Prognostic Index (p = 0.076). In the female group and group of the patients without bulky tumor mass, treated with chemotherapeutic regimens including rituximab, methylation of p15 was significantly related to longer overall survival (p = 0.036 and 0.027, respectively). Our results suggest that promoter methylation of p15 gene could have prognostic value in DLBCL patients treated with rituximab when used in combination with gender and tumor size.
T2  - Clinical and Translational Science / CTS
T1  - Hypermethylation of p15 Gene in Diffuse - Large B-Cell Lymphoma: Association with Less Aggressiveness of the Disease
VL  - 7
IS  - 5
SP  - 384
EP  - 390
DO  - 10.1111/cts.12162
ER  - 

@article{
author = "Krajnović, Milena M. and Jovanovic, Maja Perunicic and Mihaljevic, Biljana and Andelic, Bosko and Tarabar, Olivera and Knežević-Ušaj, Slavica and Krtolica-Žikić, Koviljka",
year = "2014",
abstract = "In this study, methylation-specific polymerase chain reaction was used to investigate the potential prognostic significance of the methylation status of p15, p16, MGMT, and DAPK genes in 51 specimens of diffuse large B-cell lymphoma (DLBCL). Hypermethylation of p15 gene was significantly more prevalent in patients without relapse (p = 0.001) and there was a trend toward more frequent presence of p15 methylation in patients without death outcome within 5-year follow-up period (p = 0.086) Also, there was a trend toward accumulation of p15 methylation with favorable clinicopathological parameters including: age 60 years (p = 0.091), normal levels of lactate dehydrogenase (p = 0.090), Eastern Cooperative Oncology Group performance status LT 2 (p = 0.095), and low/intermediate low International Prognostic Index (p = 0.076). In the female group and group of the patients without bulky tumor mass, treated with chemotherapeutic regimens including rituximab, methylation of p15 was significantly related to longer overall survival (p = 0.036 and 0.027, respectively). Our results suggest that promoter methylation of p15 gene could have prognostic value in DLBCL patients treated with rituximab when used in combination with gender and tumor size.",
journal = "Clinical and Translational Science / CTS",
title = "Hypermethylation of p15 Gene in Diffuse - Large B-Cell Lymphoma: Association with Less Aggressiveness of the Disease",
volume = "7",
number = "5",
pages = "384-390",
doi = "10.1111/cts.12162"
}

Krajnović, M. M., Jovanovic, M. P., Mihaljevic, B., Andelic, B., Tarabar, O., Knežević-Ušaj, S.,& Krtolica-Žikić, K.. (2014). Hypermethylation of p15 Gene in Diffuse - Large B-Cell Lymphoma: Association with Less Aggressiveness of the Disease. in Clinical and Translational Science / CTS, 7(5), 384-390.
https://doi.org/10.1111/cts.12162

Krajnović MM, Jovanovic MP, Mihaljevic B, Andelic B, Tarabar O, Knežević-Ušaj S, Krtolica-Žikić K. Hypermethylation of p15 Gene in Diffuse - Large B-Cell Lymphoma: Association with Less Aggressiveness of the Disease. in Clinical and Translational Science / CTS. 2014;7(5):384-390.
doi:10.1111/cts.12162 .

Krajnović, Milena M., Jovanovic, Maja Perunicic, Mihaljevic, Biljana, Andelic, Bosko, Tarabar, Olivera, Knežević-Ušaj, Slavica, Krtolica-Žikić, Koviljka, "Hypermethylation of p15 Gene in Diffuse - Large B-Cell Lymphoma: Association with Less Aggressiveness of the Disease" in Clinical and Translational Science / CTS, 7, no. 5 (2014):384-390,
https://doi.org/10.1111/cts.12162 . .

TY  - JOUR
AU  - Krajnović, Milena M.
AU  - Radojkovic, Milica
AU  - Davidović, Radoslav S.
AU  - Dimitrijević, Bogomir B.
AU  - Krtolica-Žikić, Koviljka
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5388
AB  - In this study, methylation-specific polymerase chain reaction was used to investigate the role and potential prognostic significance of the methylation status of p16, p15, MGMT and DAPK genes in 32 specimens of follicular lymphoma (FL). Hypermethylation of p15 gene was associated with lower hemoglobin level (P = 0.020) and MGMT/DAPK comethylation with relapsed disease (P = 0.018). Among all patients with FL, there was no significant difference in the overall survival between those with hypermethylated and unmethylated of any examined genes. Therefore, we analyzed methylation in the different groups according to FL International Prognostic Index (FLIPI) and tumor grade. In the high-risk group, patients with hypermethylated p16 gene had significant lower overall survival than those with unmethylated p16 (P = 0.006) and trend toward shorter failure-free survival (P = 0.068). In the same risk group, there was a trend toward longer overall survival for patients with hypermethylated MGMT gene, compared to those with unmethylated MGMT gene (P = 0.066). p15 methylation had impact on shorter overall survival in grade I group of patients (P = 0.013), and DAPK methylation tended to have impact on shorter failure-free survival in the whole examined group (P = 0.079). Our results suggest that promotermethylation of p16 and MGMT genes could have prognostic value when used in combination with the FLIPI and p15 methylation in combination with tumor grade. Concurrent methylation of MGMT and DAPK genes could be the marker of tumor chemoresistance and disease recurrence.
T2  - Medical Oncology
T1  - Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma
VL  - 30
IS  - 1
DO  - 10.1007/s12032-012-0441-3
ER  - 

@article{
author = "Krajnović, Milena M. and Radojkovic, Milica and Davidović, Radoslav S. and Dimitrijević, Bogomir B. and Krtolica-Žikić, Koviljka",
year = "2013",
abstract = "In this study, methylation-specific polymerase chain reaction was used to investigate the role and potential prognostic significance of the methylation status of p16, p15, MGMT and DAPK genes in 32 specimens of follicular lymphoma (FL). Hypermethylation of p15 gene was associated with lower hemoglobin level (P = 0.020) and MGMT/DAPK comethylation with relapsed disease (P = 0.018). Among all patients with FL, there was no significant difference in the overall survival between those with hypermethylated and unmethylated of any examined genes. Therefore, we analyzed methylation in the different groups according to FL International Prognostic Index (FLIPI) and tumor grade. In the high-risk group, patients with hypermethylated p16 gene had significant lower overall survival than those with unmethylated p16 (P = 0.006) and trend toward shorter failure-free survival (P = 0.068). In the same risk group, there was a trend toward longer overall survival for patients with hypermethylated MGMT gene, compared to those with unmethylated MGMT gene (P = 0.066). p15 methylation had impact on shorter overall survival in grade I group of patients (P = 0.013), and DAPK methylation tended to have impact on shorter failure-free survival in the whole examined group (P = 0.079). Our results suggest that promotermethylation of p16 and MGMT genes could have prognostic value when used in combination with the FLIPI and p15 methylation in combination with tumor grade. Concurrent methylation of MGMT and DAPK genes could be the marker of tumor chemoresistance and disease recurrence.",
journal = "Medical Oncology",
title = "Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma",
volume = "30",
number = "1",
doi = "10.1007/s12032-012-0441-3"
}

Krajnović, M. M., Radojkovic, M., Davidović, R. S., Dimitrijević, B. B.,& Krtolica-Žikić, K.. (2013). Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma. in Medical Oncology, 30(1).
https://doi.org/10.1007/s12032-012-0441-3

Krajnović MM, Radojkovic M, Davidović RS, Dimitrijević BB, Krtolica-Žikić K. Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma. in Medical Oncology. 2013;30(1).
doi:10.1007/s12032-012-0441-3 .

Krajnović, Milena M., Radojkovic, Milica, Davidović, Radoslav S., Dimitrijević, Bogomir B., Krtolica-Žikić, Koviljka, "Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma" in Medical Oncology, 30, no. 1 (2013),
https://doi.org/10.1007/s12032-012-0441-3 . .

TY  - JOUR
AU  - Kurtovic, Nada Kraguljac
AU  - Krajnović, Milena M.
AU  - Bogdanović, Andrija
AU  - Suvajdzic, Nada
AU  - Jovanović, Jelica
AU  - Dimitrijević, Bogomir B.
AU  - Čolović, Milica
AU  - Krtolica-Žikić, Koviljka
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5173
AB  - In this study, methylation-specific polymerase chain reaction (MS-PCR) was used to define the methylation status of the target promoter sequences of p15 and MGMT genes in the group of 21 adult patients with acute myeloid leukemia (AML). The incidence of aberrant hypermethylation of p15 gene (71 %) was higher comparing to MGMT gene (33 %), whereas concomitant methylation of both genes had 24 % of the patients. Although the incidence of cytogenetic abnormalities between the groups with a different methylation status of p15 and/or MGMT genes was not significantly different, we observed general trend of clustering of abnormalities with adverse prognosis into groups with concomitant hypermethylation of both genes and only p15 gene. Also, we showed that AML patients with concomitant methylation of p15/MGMT genes had a higher proportion of leukemic blast cells characterized with specific expression of individual leukocyte surface antigens (CD117(+)/CD7(+)/CD34(+)/CD15(-)), indicating leukemic cells as early myeloid progenitors. Although we could not prove that hypermethylation of p15 and/or MGMT genes is predictive parameter for response to therapy and overall survival, we noticed that AML patients with comethylated p15/MGMT genes or methylated p15 gene exhibited a higher frequency of early death, lower frequency of complete remissions as well as a trend for shorter overall survival. Assessing of the methylation status of p15 and MGMT genes may allow stratification of patients with AML into distinct groups with potentially different prognosis.
T2  - Medical Oncology
T1  - Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells
VL  - 29
IS  - 5
SP  - 3547
EP  - 3556
DO  - 10.1007/s12032-012-0289-6
ER  - 

@article{
author = "Kurtovic, Nada Kraguljac and Krajnović, Milena M. and Bogdanović, Andrija and Suvajdzic, Nada and Jovanović, Jelica and Dimitrijević, Bogomir B. and Čolović, Milica and Krtolica-Žikić, Koviljka",
year = "2012",
abstract = "In this study, methylation-specific polymerase chain reaction (MS-PCR) was used to define the methylation status of the target promoter sequences of p15 and MGMT genes in the group of 21 adult patients with acute myeloid leukemia (AML). The incidence of aberrant hypermethylation of p15 gene (71 %) was higher comparing to MGMT gene (33 %), whereas concomitant methylation of both genes had 24 % of the patients. Although the incidence of cytogenetic abnormalities between the groups with a different methylation status of p15 and/or MGMT genes was not significantly different, we observed general trend of clustering of abnormalities with adverse prognosis into groups with concomitant hypermethylation of both genes and only p15 gene. Also, we showed that AML patients with concomitant methylation of p15/MGMT genes had a higher proportion of leukemic blast cells characterized with specific expression of individual leukocyte surface antigens (CD117(+)/CD7(+)/CD34(+)/CD15(-)), indicating leukemic cells as early myeloid progenitors. Although we could not prove that hypermethylation of p15 and/or MGMT genes is predictive parameter for response to therapy and overall survival, we noticed that AML patients with comethylated p15/MGMT genes or methylated p15 gene exhibited a higher frequency of early death, lower frequency of complete remissions as well as a trend for shorter overall survival. Assessing of the methylation status of p15 and MGMT genes may allow stratification of patients with AML into distinct groups with potentially different prognosis.",
journal = "Medical Oncology",
title = "Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells",
volume = "29",
number = "5",
pages = "3547-3556",
doi = "10.1007/s12032-012-0289-6"
}

Kurtovic, N. K., Krajnović, M. M., Bogdanović, A., Suvajdzic, N., Jovanović, J., Dimitrijević, B. B., Čolović, M.,& Krtolica-Žikić, K.. (2012). Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells. in Medical Oncology, 29(5), 3547-3556.
https://doi.org/10.1007/s12032-012-0289-6

Kurtovic NK, Krajnović MM, Bogdanović A, Suvajdzic N, Jovanović J, Dimitrijević BB, Čolović M, Krtolica-Žikić K. Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells. in Medical Oncology. 2012;29(5):3547-3556.
doi:10.1007/s12032-012-0289-6 .

Kurtovic, Nada Kraguljac, Krajnović, Milena M., Bogdanović, Andrija, Suvajdzic, Nada, Jovanović, Jelica, Dimitrijević, Bogomir B., Čolović, Milica, Krtolica-Žikić, Koviljka, "Concomitant aberrant methylation of p15 and MGMT genes in acute myeloid leukemia: association with a particular immunophenotype of blast cells" in Medical Oncology, 29, no. 5 (2012):3547-3556,
https://doi.org/10.1007/s12032-012-0289-6 . .

TY  - CONF
AU  - Bogdanović, G.
AU  - Usaj-Knežević, S.
AU  - Krajnović, Milena M.
AU  - Kojić, Vesna
AU  - Nikin, Z.
AU  - Petrovic, T.
AU  - Krtolica-Žikić, Koviljka
AU  - Popsavin, M.
AU  - Krtolica, A.
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/6991
C3  - European Journal of Cancer
T1  - Cellular and Molecular Characteristics of Novel Colon Cancer Cell Line
VL  - 48
SP  - S86
EP  - S86
DO  - 10.1016/S0959-8049(12)71043-2
ER  - 

@conference{
author = "Bogdanović, G. and Usaj-Knežević, S. and Krajnović, Milena M. and Kojić, Vesna and Nikin, Z. and Petrovic, T. and Krtolica-Žikić, Koviljka and Popsavin, M. and Krtolica, A.",
year = "2012",
journal = "European Journal of Cancer",
title = "Cellular and Molecular Characteristics of Novel Colon Cancer Cell Line",
volume = "48",
pages = "S86-S86",
doi = "10.1016/S0959-8049(12)71043-2"
}

Bogdanović, G., Usaj-Knežević, S., Krajnović, M. M., Kojić, V., Nikin, Z., Petrovic, T., Krtolica-Žikić, K., Popsavin, M.,& Krtolica, A.. (2012). Cellular and Molecular Characteristics of Novel Colon Cancer Cell Line. in European Journal of Cancer, 48, S86-S86.
https://doi.org/10.1016/S0959-8049(12)71043-2

Bogdanović G, Usaj-Knežević S, Krajnović MM, Kojić V, Nikin Z, Petrovic T, Krtolica-Žikić K, Popsavin M, Krtolica A. Cellular and Molecular Characteristics of Novel Colon Cancer Cell Line. in European Journal of Cancer. 2012;48:S86-S86.
doi:10.1016/S0959-8049(12)71043-2 .

Bogdanović, G., Usaj-Knežević, S., Krajnović, Milena M., Kojić, Vesna, Nikin, Z., Petrovic, T., Krtolica-Žikić, Koviljka, Popsavin, M., Krtolica, A., "Cellular and Molecular Characteristics of Novel Colon Cancer Cell Line" in European Journal of Cancer, 48 (2012):S86-S86,
https://doi.org/10.1016/S0959-8049(12)71043-2 . .

TY  - JOUR
AU  - Todorić-Živanović, B.
AU  - Strnad, M.
AU  - Stamatovic, D.
AU  - Tukic, L.
AU  - Krtolica-Žikić, Koviljka
AU  - Tatomirovic, Z.
AU  - Đorđević, Vesna R.
AU  - Bogdanović, A.
AU  - Janković, G.
AU  - Magic, Z.
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4406
T2  - Journal of BUON
T1  - Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia (vol 16, pg 104, 2011)
VL  - 16
IS  - 2
UR  - https://hdl.handle.net/21.15107/rcub_vinar_4406
ER  - 

@article{
author = "Todorić-Živanović, B. and Strnad, M. and Stamatovic, D. and Tukic, L. and Krtolica-Žikić, Koviljka and Tatomirovic, Z. and Đorđević, Vesna R. and Bogdanović, A. and Janković, G. and Magic, Z.",
year = "2011",
journal = "Journal of BUON",
title = "Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia (vol 16, pg 104, 2011)",
volume = "16",
number = "2",
url = "https://hdl.handle.net/21.15107/rcub_vinar_4406"
}

Todorić-Živanović, B., Strnad, M., Stamatovic, D., Tukic, L., Krtolica-Žikić, K., Tatomirovic, Z., Đorđević, V. R., Bogdanović, A., Janković, G.,& Magic, Z.. (2011). Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia (vol 16, pg 104, 2011). in Journal of BUON, 16(2).
https://hdl.handle.net/21.15107/rcub_vinar_4406

Todorić-Živanović B, Strnad M, Stamatovic D, Tukic L, Krtolica-Žikić K, Tatomirovic Z, Đorđević VR, Bogdanović A, Janković G, Magic Z. Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia (vol 16, pg 104, 2011). in Journal of BUON. 2011;16(2).
https://hdl.handle.net/21.15107/rcub_vinar_4406 .

Todorić-Živanović, B., Strnad, M., Stamatovic, D., Tukic, L., Krtolica-Žikić, Koviljka, Tatomirovic, Z., Đorđević, Vesna R., Bogdanović, A., Janković, G., Magic, Z., "Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia (vol 16, pg 104, 2011)" in Journal of BUON, 16, no. 2 (2011),
https://hdl.handle.net/21.15107/rcub_vinar_4406 .

TY  - JOUR
AU  - Todorić-Živanović, B.
AU  - Strnad, M.
AU  - Stamatovic, D.
AU  - Tukic, L.
AU  - Krtolica-Žikić, Koviljka
AU  - Tatomirovic, Z.
AU  - Đorđević, Vesna R.
AU  - Bogdanović, A.
AU  - Janković, G.
AU  - Magic, Z.
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4272
AB  - Purpose: The aim of this study was to analyze the occurrence of the most frequent BCR-ABL transcript variants (b3a2, b2a2 and ela2) in Serbian patients with chronic myeloid leukemia (CML) and compare it with the occurrence reported in other populations. Methods: We analyzed peripheral blood and bone marrow samples of 136 Serbian patients with CML by RT-PCR and cytogenetic methods. Results: In 100 patients (73.5%) the b3a2 and in 34 (25%) the b2a2 forms of BCR-ABL were detected. One (0.75%) patient was BCR-ABL negative, but in lymphoblastic transformation he expressed the ela1 transcript of BCR-ABL. One (0.75%) patient displayed both b2a2 and b3a2 forms of BCR-ABL. Analysis of this group according to karyotype showed b3a2 predominance (79%) in patients with classic t(9;22); b2a2 was found in 20% and both b2a2 and b3a2 forms in 1%. In variant translocations b3a2 in 65% and b2a2 in 35% of the patients were detected. In contrast, the subgroup with normal karyotype expressed slight predominance of the b2a2 form (50%); b3a2 was found in 43% of the patients and one patient (7%) displayed ela2. Conclusion: Predominance of the b3a2 form in Serbian patients with CML is in concordance with other relevant investigations, conducted mostly on Caucasian ethnic groups, but in contrast to the study performed on the Mestizo ethnic group in Ecuador Slight predominance of the b2a2 form was also noticed among the patients with normal karyotype.
T2  - Journal of BUON
T1  - Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia
VL  - 16
IS  - 1
SP  - 104
EP  - 107
UR  - https://hdl.handle.net/21.15107/rcub_vinar_4272
ER  - 

@article{
author = "Todorić-Živanović, B. and Strnad, M. and Stamatovic, D. and Tukic, L. and Krtolica-Žikić, Koviljka and Tatomirovic, Z. and Đorđević, Vesna R. and Bogdanović, A. and Janković, G. and Magic, Z.",
year = "2011",
abstract = "Purpose: The aim of this study was to analyze the occurrence of the most frequent BCR-ABL transcript variants (b3a2, b2a2 and ela2) in Serbian patients with chronic myeloid leukemia (CML) and compare it with the occurrence reported in other populations. Methods: We analyzed peripheral blood and bone marrow samples of 136 Serbian patients with CML by RT-PCR and cytogenetic methods. Results: In 100 patients (73.5%) the b3a2 and in 34 (25%) the b2a2 forms of BCR-ABL were detected. One (0.75%) patient was BCR-ABL negative, but in lymphoblastic transformation he expressed the ela1 transcript of BCR-ABL. One (0.75%) patient displayed both b2a2 and b3a2 forms of BCR-ABL. Analysis of this group according to karyotype showed b3a2 predominance (79%) in patients with classic t(9;22); b2a2 was found in 20% and both b2a2 and b3a2 forms in 1%. In variant translocations b3a2 in 65% and b2a2 in 35% of the patients were detected. In contrast, the subgroup with normal karyotype expressed slight predominance of the b2a2 form (50%); b3a2 was found in 43% of the patients and one patient (7%) displayed ela2. Conclusion: Predominance of the b3a2 form in Serbian patients with CML is in concordance with other relevant investigations, conducted mostly on Caucasian ethnic groups, but in contrast to the study performed on the Mestizo ethnic group in Ecuador Slight predominance of the b2a2 form was also noticed among the patients with normal karyotype.",
journal = "Journal of BUON",
title = "Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia",
volume = "16",
number = "1",
pages = "104-107",
url = "https://hdl.handle.net/21.15107/rcub_vinar_4272"
}

Todorić-Živanović, B., Strnad, M., Stamatovic, D., Tukic, L., Krtolica-Žikić, K., Tatomirovic, Z., Đorđević, V. R., Bogdanović, A., Janković, G.,& Magic, Z.. (2011). Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia. in Journal of BUON, 16(1), 104-107.
https://hdl.handle.net/21.15107/rcub_vinar_4272

Todorić-Živanović B, Strnad M, Stamatovic D, Tukic L, Krtolica-Žikić K, Tatomirovic Z, Đorđević VR, Bogdanović A, Janković G, Magic Z. Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia. in Journal of BUON. 2011;16(1):104-107.
https://hdl.handle.net/21.15107/rcub_vinar_4272 .

Todorić-Živanović, B., Strnad, M., Stamatovic, D., Tukic, L., Krtolica-Žikić, Koviljka, Tatomirovic, Z., Đorđević, Vesna R., Bogdanović, A., Janković, G., Magic, Z., "Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia" in Journal of BUON, 16, no. 1 (2011):104-107,
https://hdl.handle.net/21.15107/rcub_vinar_4272 .

TY  - JOUR
AU  - Kurtovic, Nada Kraguljac
AU  - Krajnović, Milena M.
AU  - Dimitrijević, Bogomir B.
AU  - Mihaljevic, Biljana
AU  - Gotić, Mirjana
AU  - Krtolica-Žikić, Koviljka
PY  - 2010
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4045
AB  - The methylation status of the target promoter sequences of p15(INK4B) (p15) and O-6-methylguanine-DNA methyltransferase (MGMT) genes was studied by methylation-specific PCR in 10 adult patients with de novo B-cell non-Hodgkin lymphoma (B-NHL). The aberrant hypermethylation of the p15 gene was more frequent (50%) compared to the hypermethylation of the MGMT gene (30%), and was detected in different types of B-NHL in both genes. Hypermethylation of the MGMT gene occurred exclusively in association with the hypermethylation of the p15 gene. All lymphoma patients with hypermethylation of the p15 and/or MGMT genes had a higher clinical stage of the disease (IV - V). We show the association of anemia and/or thrombocytopenia with the hypermethylation of the p15 gene, ascribing the p15 gene as a potential prognostic marker in B-NHL. Comethylation of MGMT with the p15 gene represents a novel finding and presents both genes as candidates for future studies of the hypermethylation profiles of B-NHL.
T2  - Archives of Biological Sciences
T1  - Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study
VL  - 62
IS  - 2
SP  - 211
EP  - 221
DO  - 10.2298/ABS1002211K
ER  - 

@article{
author = "Kurtovic, Nada Kraguljac and Krajnović, Milena M. and Dimitrijević, Bogomir B. and Mihaljevic, Biljana and Gotić, Mirjana and Krtolica-Žikić, Koviljka",
year = "2010",
abstract = "The methylation status of the target promoter sequences of p15(INK4B) (p15) and O-6-methylguanine-DNA methyltransferase (MGMT) genes was studied by methylation-specific PCR in 10 adult patients with de novo B-cell non-Hodgkin lymphoma (B-NHL). The aberrant hypermethylation of the p15 gene was more frequent (50%) compared to the hypermethylation of the MGMT gene (30%), and was detected in different types of B-NHL in both genes. Hypermethylation of the MGMT gene occurred exclusively in association with the hypermethylation of the p15 gene. All lymphoma patients with hypermethylation of the p15 and/or MGMT genes had a higher clinical stage of the disease (IV - V). We show the association of anemia and/or thrombocytopenia with the hypermethylation of the p15 gene, ascribing the p15 gene as a potential prognostic marker in B-NHL. Comethylation of MGMT with the p15 gene represents a novel finding and presents both genes as candidates for future studies of the hypermethylation profiles of B-NHL.",
journal = "Archives of Biological Sciences",
title = "Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study",
volume = "62",
number = "2",
pages = "211-221",
doi = "10.2298/ABS1002211K"
}

Kurtovic, N. K., Krajnović, M. M., Dimitrijević, B. B., Mihaljevic, B., Gotić, M.,& Krtolica-Žikić, K.. (2010). Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study. in Archives of Biological Sciences, 62(2), 211-221.
https://doi.org/10.2298/ABS1002211K

Kurtovic NK, Krajnović MM, Dimitrijević BB, Mihaljevic B, Gotić M, Krtolica-Žikić K. Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study. in Archives of Biological Sciences. 2010;62(2):211-221.
doi:10.2298/ABS1002211K .

Kurtovic, Nada Kraguljac, Krajnović, Milena M., Dimitrijević, Bogomir B., Mihaljevic, Biljana, Gotić, Mirjana, Krtolica-Žikić, Koviljka, "Frequency of Aberrant Promoter Methylation of P15(Ink4b) and O-6-Methylguanine-Dna Methyltransferase Genes in B-Cell Non-Hodgkin Lymphoma: a Pilot Study" in Archives of Biological Sciences, 62, no. 2 (2010):211-221,
https://doi.org/10.2298/ABS1002211K . .

TY  - JOUR
AU  - Radojkovic, M.
AU  - Ristic, S.
AU  - Colovic, M.
AU  - Cemerikic-Martinovic, V.
AU  - Radojkovic, D.
AU  - Krtolica-Žikić, Koviljka
PY  - 2008
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3527
AB  - Follicular lymphoma (FL) is characterized by the presence of a t(14; 18) chromosomal translocation that results in overexpression of bcl-2 protein. Bcl-2/IgH gene rearrangement is detected in 80-90% of follicular lymphomas in Western countries. The aim of this study was to analyze the bcl-2/IgH rearrangement in FL lymphoma patients in Serbia, by PCR technique, correlate molecular findings with clinical characteristics and outcome and assess the prognostic significance of these rearrangements. One hundred-seven patients (median age, 54 years; male/female ratio:60/47) diagnosed with FL were included in the study. DNA samples were obtained from paraffin embedded lymphoid tissue of patients. Bcl-2/IgH rearrangement was assessed for the major breakpoint region (MBR), 5MBR and the minor cluster region (mcr) breakpoints by PCR technique. We detected a t(14;18) in 81.3% (87/107) of patients. The distribution of bcl-2-IgH rearrangement was as follows: 88,5% (77/87) in MBR breakpoint, 10,35% (9/87) in 5MBR, whereas mcr bcl-2-IgH rearrangement was observed in one patient (1.15%). No rearrangements were detected in remaining 20 patients (18.7%). This is the first analyses of the frequency of the bcl-2/IgH gene rearrangement in Serbian FL patients, as well as in Eastern European countries. There was no correlation between presence of bcl-2/IgH gene rearrangement and clinical outcome of disease. Incidence of bcl-2/IgH gene rearrangement in Serbian FL patients is relatively high, and similar to frequency in Western countries. Presence of this rearrangement in tumor tissue is not of prognostic significance.
T2  - Neoplasma
T1  - Molecular characteristics and prognostic significance of bcl-2/IgH gene rearrangement in Serbian follicular lymphoma patients
VL  - 55
IS  - 5
SP  - 421
EP  - 427
UR  - https://hdl.handle.net/21.15107/rcub_vinar_3527
ER  - 

@article{
author = "Radojkovic, M. and Ristic, S. and Colovic, M. and Cemerikic-Martinovic, V. and Radojkovic, D. and Krtolica-Žikić, Koviljka",
year = "2008",
abstract = "Follicular lymphoma (FL) is characterized by the presence of a t(14; 18) chromosomal translocation that results in overexpression of bcl-2 protein. Bcl-2/IgH gene rearrangement is detected in 80-90% of follicular lymphomas in Western countries. The aim of this study was to analyze the bcl-2/IgH rearrangement in FL lymphoma patients in Serbia, by PCR technique, correlate molecular findings with clinical characteristics and outcome and assess the prognostic significance of these rearrangements. One hundred-seven patients (median age, 54 years; male/female ratio:60/47) diagnosed with FL were included in the study. DNA samples were obtained from paraffin embedded lymphoid tissue of patients. Bcl-2/IgH rearrangement was assessed for the major breakpoint region (MBR), 5MBR and the minor cluster region (mcr) breakpoints by PCR technique. We detected a t(14;18) in 81.3% (87/107) of patients. The distribution of bcl-2-IgH rearrangement was as follows: 88,5% (77/87) in MBR breakpoint, 10,35% (9/87) in 5MBR, whereas mcr bcl-2-IgH rearrangement was observed in one patient (1.15%). No rearrangements were detected in remaining 20 patients (18.7%). This is the first analyses of the frequency of the bcl-2/IgH gene rearrangement in Serbian FL patients, as well as in Eastern European countries. There was no correlation between presence of bcl-2/IgH gene rearrangement and clinical outcome of disease. Incidence of bcl-2/IgH gene rearrangement in Serbian FL patients is relatively high, and similar to frequency in Western countries. Presence of this rearrangement in tumor tissue is not of prognostic significance.",
journal = "Neoplasma",
title = "Molecular characteristics and prognostic significance of bcl-2/IgH gene rearrangement in Serbian follicular lymphoma patients",
volume = "55",
number = "5",
pages = "421-427",
url = "https://hdl.handle.net/21.15107/rcub_vinar_3527"
}

Radojkovic, M., Ristic, S., Colovic, M., Cemerikic-Martinovic, V., Radojkovic, D.,& Krtolica-Žikić, K.. (2008). Molecular characteristics and prognostic significance of bcl-2/IgH gene rearrangement in Serbian follicular lymphoma patients. in Neoplasma, 55(5), 421-427.
https://hdl.handle.net/21.15107/rcub_vinar_3527

Radojkovic M, Ristic S, Colovic M, Cemerikic-Martinovic V, Radojkovic D, Krtolica-Žikić K. Molecular characteristics and prognostic significance of bcl-2/IgH gene rearrangement in Serbian follicular lymphoma patients. in Neoplasma. 2008;55(5):421-427.
https://hdl.handle.net/21.15107/rcub_vinar_3527 .

Radojkovic, M., Ristic, S., Colovic, M., Cemerikic-Martinovic, V., Radojkovic, D., Krtolica-Žikić, Koviljka, "Molecular characteristics and prognostic significance of bcl-2/IgH gene rearrangement in Serbian follicular lymphoma patients" in Neoplasma, 55, no. 5 (2008):421-427,
https://hdl.handle.net/21.15107/rcub_vinar_3527 .

TY  - JOUR
AU  - Krtolica-Žikić, Koviljka
AU  - Krajnović, Milena M.
AU  - Usaj-Knežević, Slavica
AU  - Babić, Dragan
AU  - Jovanovic, Dusan
AU  - Dimitrijević, Bogomir B.
PY  - 2007
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3184
AB  - AIM: To investigate the significance of p16 and O-6- methylguanine-DNA methyltransferase (MGMT) genes promoter hypermethylation and K-ras mutations on colorectal tumorigenesis and progression. METHODS: p16 and MGMT methylation status was examined on 47 tumor samples, and K-ras mutational status was examined on 85 tumor samples. For methylation analysis, a methylation specific PCR (MS-PCR) method was used. RESULTS: p16 and MGMT promoter methylation was found in 51% (24/47) and 43% (20/47) of CRCS, respectively, and the K-ras mutation was found in 44% (37/85) of CRCs. Comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease within a two-year period of observation. Only 27% of patients with simultaneous p16 and MGMT methylation showed the detectible occurrence of metastasis and/or death, compared to 67% of patients without double methylation or with no methylation (3/11 vs 22/33, P LT 0.05, chi(2)-test). In addition, p16 and MGMT comethylation showed a trend toward an association with longer survival in patients with CRCs (35.5 +/- 6.0 mo vs 23.1 +/- 3.2 mo, P = 0.072, Log-rank test). Progression of the disease within a two-year period was observed in 66% of patients carrying the K-ras mutation, compared to only 19% of patients with wild type K-ras (29/44 vs 7/37, P LT 0.001, chi(2)-test). The presence of the K-ras mutation significantly correlated to shortened overall survival (20.0 +/- 1.9 mo vs 37.0 +/- 1.8 mo, P LT 0.001, Log-rank test). The comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease even when K-ras mutations were included in the analysis as an independent variable. CONCLUSION: Our data suggest that comethylation of promoters of p16 and MGMT genes could have a prognostic value in patients with CRC. Specifically, concurrent methylation of both genes correlates with better prognosis. (C) 2007 The WJG Press. All rights reserved.
T2  - World Journal of Gastroenterology
T1  - Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value
VL  - 13
IS  - 8
SP  - 1187
EP  - 1194
DO  - 10.3748/wjg.v13.i8.1187
ER  - 

@article{
author = "Krtolica-Žikić, Koviljka and Krajnović, Milena M. and Usaj-Knežević, Slavica and Babić, Dragan and Jovanovic, Dusan and Dimitrijević, Bogomir B.",
year = "2007",
abstract = "AIM: To investigate the significance of p16 and O-6- methylguanine-DNA methyltransferase (MGMT) genes promoter hypermethylation and K-ras mutations on colorectal tumorigenesis and progression. METHODS: p16 and MGMT methylation status was examined on 47 tumor samples, and K-ras mutational status was examined on 85 tumor samples. For methylation analysis, a methylation specific PCR (MS-PCR) method was used. RESULTS: p16 and MGMT promoter methylation was found in 51% (24/47) and 43% (20/47) of CRCS, respectively, and the K-ras mutation was found in 44% (37/85) of CRCs. Comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease within a two-year period of observation. Only 27% of patients with simultaneous p16 and MGMT methylation showed the detectible occurrence of metastasis and/or death, compared to 67% of patients without double methylation or with no methylation (3/11 vs 22/33, P LT 0.05, chi(2)-test). In addition, p16 and MGMT comethylation showed a trend toward an association with longer survival in patients with CRCs (35.5 +/- 6.0 mo vs 23.1 +/- 3.2 mo, P = 0.072, Log-rank test). Progression of the disease within a two-year period was observed in 66% of patients carrying the K-ras mutation, compared to only 19% of patients with wild type K-ras (29/44 vs 7/37, P LT 0.001, chi(2)-test). The presence of the K-ras mutation significantly correlated to shortened overall survival (20.0 +/- 1.9 mo vs 37.0 +/- 1.8 mo, P LT 0.001, Log-rank test). The comethylation of p16 and MGMT genes was significantly associated with lower aggressiveness of the disease even when K-ras mutations were included in the analysis as an independent variable. CONCLUSION: Our data suggest that comethylation of promoters of p16 and MGMT genes could have a prognostic value in patients with CRC. Specifically, concurrent methylation of both genes correlates with better prognosis. (C) 2007 The WJG Press. All rights reserved.",
journal = "World Journal of Gastroenterology",
title = "Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value",
volume = "13",
number = "8",
pages = "1187-1194",
doi = "10.3748/wjg.v13.i8.1187"
}

Krtolica-Žikić, K., Krajnović, M. M., Usaj-Knežević, S., Babić, D., Jovanovic, D.,& Dimitrijević, B. B.. (2007). Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value. in World Journal of Gastroenterology, 13(8), 1187-1194.
https://doi.org/10.3748/wjg.v13.i8.1187

Krtolica-Žikić K, Krajnović MM, Usaj-Knežević S, Babić D, Jovanovic D, Dimitrijević BB. Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value. in World Journal of Gastroenterology. 2007;13(8):1187-1194.
doi:10.3748/wjg.v13.i8.1187 .

Krtolica-Žikić, Koviljka, Krajnović, Milena M., Usaj-Knežević, Slavica, Babić, Dragan, Jovanovic, Dusan, Dimitrijević, Bogomir B., "Comethylation of p16 and MGMT genes in colorectal carcinoma: Correlation with clinicopathological features and prognostic value" in World Journal of Gastroenterology, 13, no. 8 (2007):1187-1194,
https://doi.org/10.3748/wjg.v13.i8.1187 . .

TY  - JOUR
AU  - Mandušić, Vesna
AU  - Krtolica-Žikić, Koviljka
AU  - Nikolić-Vukosavljević, Dragica
AU  - Popov-Celeketic, D.
AU  - Plećaš, D.
AU  - Boricic, I.
AU  - Dimitrijević, Bogomir B.
AU  - Tanić, Nikola
PY  - 2007
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3414
T2  - Archives of Biological Sciences
T1  - Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.
VL  - 59
IS  - 2
SP  - 15P
EP  - 16P
DO  - 10.2298/ABS070215PM
ER  - 

@article{
author = "Mandušić, Vesna and Krtolica-Žikić, Koviljka and Nikolić-Vukosavljević, Dragica and Popov-Celeketic, D. and Plećaš, D. and Boricic, I. and Dimitrijević, Bogomir B. and Tanić, Nikola",
year = "2007",
journal = "Archives of Biological Sciences",
title = "Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.",
volume = "59",
number = "2",
pages = "15P-16P",
doi = "10.2298/ABS070215PM"
}

Mandušić, V., Krtolica-Žikić, K., Nikolić-Vukosavljević, D., Popov-Celeketic, D., Plećaš, D., Boricic, I., Dimitrijević, B. B.,& Tanić, N.. (2007). Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.. in Archives of Biological Sciences, 59(2), 15P-16P.
https://doi.org/10.2298/ABS070215PM

Mandušić V, Krtolica-Žikić K, Nikolić-Vukosavljević D, Popov-Celeketic D, Plećaš D, Boricic I, Dimitrijević BB, Tanić N. Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues.. in Archives of Biological Sciences. 2007;59(2):15P-16P.
doi:10.2298/ABS070215PM .

Mandušić, Vesna, Krtolica-Žikić, Koviljka, Nikolić-Vukosavljević, Dragica, Popov-Celeketic, D., Plećaš, D., Boricic, I., Dimitrijević, Bogomir B., Tanić, Nikola, "Transcriptional ratio of estrogen receptor beta mRNAs in carcinomas and in normal tissues." in Archives of Biological Sciences, 59, no. 2 (2007):15P-16P,
https://doi.org/10.2298/ABS070215PM . .

TY  - JOUR
AU  - Bogdanović, Gordana
AU  - Jurišić, Vladimir
AU  - Kraguljac, Nada
AU  - Mrđanović, Jasminka Ž.
AU  - Jakimov, Dimitar
AU  - Krtolica-Žikić, Koviljka
AU  - Krajnović, Milena M.
AU  - Magic, Zvonko
AU  - Stojiljković, Bratislav
AU  - Andrijevic, Ljiljana
AU  - Srdić, Tatjana
AU  - Baltic, Mirjana
AU  - Popovic, Stevan
PY  - 2007
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3219
AB  - We report on characteristics of the first human cell line, PC-MDS, derived from a bone marrow of a patient with therapy-related myelodysplastic syndrome (t-MDS) who had no overt post-MDS leukemia. Classic cytology analyses, immunophenotyping, cytogenetic and molecular genetic procedures were used for characterization of the cell line. PC-MDS cells are positive for the expression of CD13, CD15, CD30, CD33, and CD45 antigen. Positive cytochemical staining and immunophenotype analyses indicated that PC-MDS cells have some characteristics of the early myeloid precursor cell. The karyotype analysis of PC-MDS cell line revealed various numerical and structural changes including those typically associated with t-MDS: del(5)(q13)[7], der(5)t(5;11)(p11;q11)[13], -7[6], del(7)(q31)[2], +20[3], -20[4]. Evaluation of methylation status in a promoter region of p 15, p 16 and MGMT genes showed biallelic hypermethylation pattern of 5 promoter region only in MGMT gene. PC-MDS is the first t-MDS derived cell line, and based on its immunological, cytogenetic and molecular characterization could be a new tool in evaluation of complex biology of MDS and a model for methylation studies. (c) 2007 Elsevier Ltd. All rights reserved.
T2  - Leukemia Research
T1  - Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome
VL  - 31
IS  - 8
SP  - 1097
EP  - 1105
DO  - 10.1016/j.leukres.2007.01.012
ER  - 

@article{
author = "Bogdanović, Gordana and Jurišić, Vladimir and Kraguljac, Nada and Mrđanović, Jasminka Ž. and Jakimov, Dimitar and Krtolica-Žikić, Koviljka and Krajnović, Milena M. and Magic, Zvonko and Stojiljković, Bratislav and Andrijevic, Ljiljana and Srdić, Tatjana and Baltic, Mirjana and Popovic, Stevan",
year = "2007",
abstract = "We report on characteristics of the first human cell line, PC-MDS, derived from a bone marrow of a patient with therapy-related myelodysplastic syndrome (t-MDS) who had no overt post-MDS leukemia. Classic cytology analyses, immunophenotyping, cytogenetic and molecular genetic procedures were used for characterization of the cell line. PC-MDS cells are positive for the expression of CD13, CD15, CD30, CD33, and CD45 antigen. Positive cytochemical staining and immunophenotype analyses indicated that PC-MDS cells have some characteristics of the early myeloid precursor cell. The karyotype analysis of PC-MDS cell line revealed various numerical and structural changes including those typically associated with t-MDS: del(5)(q13)[7], der(5)t(5;11)(p11;q11)[13], -7[6], del(7)(q31)[2], +20[3], -20[4]. Evaluation of methylation status in a promoter region of p 15, p 16 and MGMT genes showed biallelic hypermethylation pattern of 5 promoter region only in MGMT gene. PC-MDS is the first t-MDS derived cell line, and based on its immunological, cytogenetic and molecular characterization could be a new tool in evaluation of complex biology of MDS and a model for methylation studies. (c) 2007 Elsevier Ltd. All rights reserved.",
journal = "Leukemia Research",
title = "Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome",
volume = "31",
number = "8",
pages = "1097-1105",
doi = "10.1016/j.leukres.2007.01.012"
}

Bogdanović, G., Jurišić, V., Kraguljac, N., Mrđanović, J. Ž., Jakimov, D., Krtolica-Žikić, K., Krajnović, M. M., Magic, Z., Stojiljković, B., Andrijevic, L., Srdić, T., Baltic, M.,& Popovic, S.. (2007). Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome. in Leukemia Research, 31(8), 1097-1105.
https://doi.org/10.1016/j.leukres.2007.01.012

Bogdanović G, Jurišić V, Kraguljac N, Mrđanović JŽ, Jakimov D, Krtolica-Žikić K, Krajnović MM, Magic Z, Stojiljković B, Andrijevic L, Srdić T, Baltic M, Popovic S. Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome. in Leukemia Research. 2007;31(8):1097-1105.
doi:10.1016/j.leukres.2007.01.012 .

Bogdanović, Gordana, Jurišić, Vladimir, Kraguljac, Nada, Mrđanović, Jasminka Ž., Jakimov, Dimitar, Krtolica-Žikić, Koviljka, Krajnović, Milena M., Magic, Zvonko, Stojiljković, Bratislav, Andrijevic, Ljiljana, Srdić, Tatjana, Baltic, Mirjana, Popovic, Stevan, "Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy-related myelodysplastic syndrome" in Leukemia Research, 31, no. 8 (2007):1097-1105,
https://doi.org/10.1016/j.leukres.2007.01.012 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Krtolica-Žikić, Koviljka
AU  - Krajnović, Milena M.
AU  - Dimitrijević, Bogomir B.
AU  - Konstantinovic, M.
AU  - Baltić, Vladimir
AU  - Prtenjak, Gordana
AU  - Stojiljković, Bratislav
AU  - Breberina, Milan
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2006
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3079
AB  - Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.
T2  - Clinica Chimica Acta
T1  - Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients
VL  - 371
IS  - 1-2
SP  - 191
EP  - 193
DO  - 10.1016/j.cca.2006.02.027
ER  - 

@article{
author = "Ivanović, Vesna and Demajo, Miroslav and Krtolica-Žikić, Koviljka and Krajnović, Milena M. and Dimitrijević, Bogomir B. and Konstantinovic, M. and Baltić, Vladimir and Prtenjak, Gordana and Stojiljković, Bratislav and Breberina, Milan and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica",
year = "2006",
abstract = "Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved.",
journal = "Clinica Chimica Acta",
title = "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients",
volume = "371",
number = "1-2",
pages = "191-193",
doi = "10.1016/j.cca.2006.02.027"
}

Ivanović, V., Demajo, M., Krtolica-Žikić, K., Krajnović, M. M., Dimitrijević, B. B., Konstantinovic, M., Baltić, V., Prtenjak, G., Stojiljković, B., Breberina, M., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2006). Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta, 371(1-2), 191-193.
https://doi.org/10.1016/j.cca.2006.02.027

Ivanović V, Demajo M, Krtolica-Žikić K, Krajnović MM, Dimitrijević BB, Konstantinovic M, Baltić V, Prtenjak G, Stojiljković B, Breberina M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients. in Clinica Chimica Acta. 2006;371(1-2):191-193.
doi:10.1016/j.cca.2006.02.027 .

Ivanović, Vesna, Demajo, Miroslav, Krtolica-Žikić, Koviljka, Krajnović, Milena M., Dimitrijević, Bogomir B., Konstantinovic, M., Baltić, Vladimir, Prtenjak, Gordana, Stojiljković, Bratislav, Breberina, Milan, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients" in Clinica Chimica Acta, 371, no. 1-2 (2006):191-193,
https://doi.org/10.1016/j.cca.2006.02.027 . .

TY  - JOUR
AU  - Todoric-Živanović, B
AU  - Marisavljevic, D
AU  - Surace, C
AU  - Cemerikic, V
AU  - Markovic, O
AU  - Krtolica-Žikić, Koviljka
AU  - Tatomirovic, Z
AU  - Cikota, B
AU  - Magic, Z
AU  - Rocchi, M
PY  - 2006
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3011
AB  - Chronic myeloid leukemia (CML) is a clonal malignant disorder of a pluripotent hematopoetic stem cell characterized by the presence of the Philadelphia (Ph) chromosome in more than 90% of patients. Cryptic or masked BCR/ABL gene rearrangements may be found in cases with a normal karyotype and in cases with the complex karyotype, in which typical t(9;22) is not visible at the microscopic level. Those rearrangements can now be detected by fluorescence in situ hybridization. Here, we report on a novel and complex Ph chromosome-negative CML case with a t(6;9) (p21;q34.1) in which the BCR/ABL fusion gene is located at 6p21. (c) 2006 Elsevier Inc. All rights reserved.
T2  - Cancer Genetics and Cytogenetics
T1  - A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1)
VL  - 166
IS  - 2
SP  - 180
EP  - 185
DO  - 10.1016/j.cancergencyto.2005.11.008
ER  - 

@article{
author = "Todoric-Živanović, B and Marisavljevic, D and Surace, C and Cemerikic, V and Markovic, O and Krtolica-Žikić, Koviljka and Tatomirovic, Z and Cikota, B and Magic, Z and Rocchi, M",
year = "2006",
abstract = "Chronic myeloid leukemia (CML) is a clonal malignant disorder of a pluripotent hematopoetic stem cell characterized by the presence of the Philadelphia (Ph) chromosome in more than 90% of patients. Cryptic or masked BCR/ABL gene rearrangements may be found in cases with a normal karyotype and in cases with the complex karyotype, in which typical t(9;22) is not visible at the microscopic level. Those rearrangements can now be detected by fluorescence in situ hybridization. Here, we report on a novel and complex Ph chromosome-negative CML case with a t(6;9) (p21;q34.1) in which the BCR/ABL fusion gene is located at 6p21. (c) 2006 Elsevier Inc. All rights reserved.",
journal = "Cancer Genetics and Cytogenetics",
title = "A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1)",
volume = "166",
number = "2",
pages = "180-185",
doi = "10.1016/j.cancergencyto.2005.11.008"
}

Todoric-Živanović, B., Marisavljevic, D., Surace, C., Cemerikic, V., Markovic, O., Krtolica-Žikić, K., Tatomirovic, Z., Cikota, B., Magic, Z.,& Rocchi, M.. (2006). A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1). in Cancer Genetics and Cytogenetics, 166(2), 180-185.
https://doi.org/10.1016/j.cancergencyto.2005.11.008

Todoric-Živanović B, Marisavljevic D, Surace C, Cemerikic V, Markovic O, Krtolica-Žikić K, Tatomirovic Z, Cikota B, Magic Z, Rocchi M. A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1). in Cancer Genetics and Cytogenetics. 2006;166(2):180-185.
doi:10.1016/j.cancergencyto.2005.11.008 .

Todoric-Živanović, B, Marisavljevic, D, Surace, C, Cemerikic, V, Markovic, O, Krtolica-Žikić, Koviljka, Tatomirovic, Z, Cikota, B, Magic, Z, Rocchi, M, "A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1)" in Cancer Genetics and Cytogenetics, 166, no. 2 (2006):180-185,
https://doi.org/10.1016/j.cancergencyto.2005.11.008 . .

TY  - CONF
AU  - Evi, Vesna Or
AU  - Jovanovi, J.
AU  - Todori, B.
AU  - Magi, Z.
AU  - Krtolica-Žikić, Koviljka
AU  - Bokovi, D.
PY  - 2005
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2720
C3  - Chromosome Research
T1  - Variant translocations and the forms of BCR/abl rearrangements in chronic myeloid leukemia
VL  - 13
SP  - 190
EP  - 190
UR  - https://hdl.handle.net/21.15107/rcub_vinar_2720
ER  - 

@conference{
author = "Evi, Vesna Or and Jovanovi, J. and Todori, B. and Magi, Z. and Krtolica-Žikić, Koviljka and Bokovi, D.",
year = "2005",
journal = "Chromosome Research",
title = "Variant translocations and the forms of BCR/abl rearrangements in chronic myeloid leukemia",
volume = "13",
pages = "190-190",
url = "https://hdl.handle.net/21.15107/rcub_vinar_2720"
}

Evi, V. O., Jovanovi, J., Todori, B., Magi, Z., Krtolica-Žikić, K.,& Bokovi, D.. (2005). Variant translocations and the forms of BCR/abl rearrangements in chronic myeloid leukemia. in Chromosome Research, 13, 190-190.
https://hdl.handle.net/21.15107/rcub_vinar_2720

Evi VO, Jovanovi J, Todori B, Magi Z, Krtolica-Žikić K, Bokovi D. Variant translocations and the forms of BCR/abl rearrangements in chronic myeloid leukemia. in Chromosome Research. 2005;13:190-190.
https://hdl.handle.net/21.15107/rcub_vinar_2720 .

Evi, Vesna Or, Jovanovi, J., Todori, B., Magi, Z., Krtolica-Žikić, Koviljka, Bokovi, D., "Variant translocations and the forms of BCR/abl rearrangements in chronic myeloid leukemia" in Chromosome Research, 13 (2005):190-190,
https://hdl.handle.net/21.15107/rcub_vinar_2720 .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Demajo, Miroslav
AU  - Todorović-Raković, N
AU  - Nikolić-Vukosavljević, Dragica
AU  - Nešković-Konstantinović, Zora
AU  - Krtolica-Žikić, Koviljka
AU  - Veljković, Veljko
AU  - Prljić, Jelena
AU  - Dimitrijević, Bogomir B.
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2769
AB  - Although overexpression of TGF-beta(1) protein has been demonstrated in advanced breast cancer(BC) patients, as well as in other solid tumours, the molecular mechanism of this process remains obscure. This paper proposes that a genetic/epigenetic alteration might occur in the TGF-beta(1) gene, within the region coding for the recognition site with TGF(beta) receptor type II, leading to a disruption of the ligand-receptor interaction and triggering the TGF-beta(1) cascade-related BC progression. To establish the operational framework for this hypothesis, in the present study, this recognition site was identified by the Informational Spectrum Method (ISM) to comprise two TGF-beta(1) peptides (positions 47-66 as and 83-112 aa) and one receptor peptide at positions 112-151 as of the extracellular domain of the receptor (TbetaRII(M)). The TbetaRII(M) locus was further evaluated by ISM-derived deletion analysis of the TbetaRII sequences. To provide experimental support for the proposed model, a pilot study of plasma TGF-beta(1) analysis was performed in advanced BC patients (n = 8). Two commercial ELISA assays, one with specific alphaTGF-beta(1) MAb (MAb) and other with TbetaRII(M) as the immobilized phase, revealed pronounced differences in the pattern of plasma TGF-beta(1) elevation. In MAb-profile, the TGF-beta(1) increase was detected in 7 of 8 patients, whereas analogous TbetaRII(M)-profile revealed the elevation in 3 of 8 patients, taking a 50% of maximal elevation as the cut-off value. These findings are consistent with the proposed aberration of TGF-beta(1) ligand within the TbetaRII recognition site. Summarizing, this model system is a good starting point for further genetic studies, particularly on genetic/epigenetic alterations of sequences involved in TGF-beta(1) and TbetaRII(M) interaction, with putative prognostic value for breast cancer. (C) 2004 Elsevier Ltd. All rights reserved.
T2  - Medical Hypotheses
T1  - Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer
VL  - 62
IS  - 5
SP  - 727
EP  - 732
DO  - 10.1016/j.mehy.2003.11.027
ER  - 

@article{
author = "Ivanović, Vesna and Demajo, Miroslav and Todorović-Raković, N and Nikolić-Vukosavljević, Dragica and Nešković-Konstantinović, Zora and Krtolica-Žikić, Koviljka and Veljković, Veljko and Prljić, Jelena and Dimitrijević, Bogomir B.",
year = "2004",
abstract = "Although overexpression of TGF-beta(1) protein has been demonstrated in advanced breast cancer(BC) patients, as well as in other solid tumours, the molecular mechanism of this process remains obscure. This paper proposes that a genetic/epigenetic alteration might occur in the TGF-beta(1) gene, within the region coding for the recognition site with TGF(beta) receptor type II, leading to a disruption of the ligand-receptor interaction and triggering the TGF-beta(1) cascade-related BC progression. To establish the operational framework for this hypothesis, in the present study, this recognition site was identified by the Informational Spectrum Method (ISM) to comprise two TGF-beta(1) peptides (positions 47-66 as and 83-112 aa) and one receptor peptide at positions 112-151 as of the extracellular domain of the receptor (TbetaRII(M)). The TbetaRII(M) locus was further evaluated by ISM-derived deletion analysis of the TbetaRII sequences. To provide experimental support for the proposed model, a pilot study of plasma TGF-beta(1) analysis was performed in advanced BC patients (n = 8). Two commercial ELISA assays, one with specific alphaTGF-beta(1) MAb (MAb) and other with TbetaRII(M) as the immobilized phase, revealed pronounced differences in the pattern of plasma TGF-beta(1) elevation. In MAb-profile, the TGF-beta(1) increase was detected in 7 of 8 patients, whereas analogous TbetaRII(M)-profile revealed the elevation in 3 of 8 patients, taking a 50% of maximal elevation as the cut-off value. These findings are consistent with the proposed aberration of TGF-beta(1) ligand within the TbetaRII recognition site. Summarizing, this model system is a good starting point for further genetic studies, particularly on genetic/epigenetic alterations of sequences involved in TGF-beta(1) and TbetaRII(M) interaction, with putative prognostic value for breast cancer. (C) 2004 Elsevier Ltd. All rights reserved.",
journal = "Medical Hypotheses",
title = "Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer",
volume = "62",
number = "5",
pages = "727-732",
doi = "10.1016/j.mehy.2003.11.027"
}

Ivanović, V., Demajo, M., Todorović-Raković, N., Nikolić-Vukosavljević, D., Nešković-Konstantinović, Z., Krtolica-Žikić, K., Veljković, V., Prljić, J.,& Dimitrijević, B. B.. (2004). Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer. in Medical Hypotheses, 62(5), 727-732.
https://doi.org/10.1016/j.mehy.2003.11.027

Ivanović V, Demajo M, Todorović-Raković N, Nikolić-Vukosavljević D, Nešković-Konstantinović Z, Krtolica-Žikić K, Veljković V, Prljić J, Dimitrijević BB. Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer. in Medical Hypotheses. 2004;62(5):727-732.
doi:10.1016/j.mehy.2003.11.027 .

Ivanović, Vesna, Demajo, Miroslav, Todorović-Raković, N, Nikolić-Vukosavljević, Dragica, Nešković-Konstantinović, Zora, Krtolica-Žikić, Koviljka, Veljković, Veljko, Prljić, Jelena, Dimitrijević, Bogomir B., "Localization of recognition site between transforming growth factor-beta(1) (TGF-beta(1)) and TGF beta receptor type II: possible implications in breast cancer" in Medical Hypotheses, 62, no. 5 (2004):727-732,
https://doi.org/10.1016/j.mehy.2003.11.027 . .

TY  - JOUR
AU  - Andreyev, HJN
AU  - Benamouzig, R
AU  - Beranek, M
AU  - Clarke, P
AU  - Cunningham, D
AU  - Norman, AR
AU  - Giaretti, W
AU  - de Goeij, AFPM
AU  - Iacopetta, BJ
AU  - Jullian, E
AU  - Krtolica-Žikić, Koviljka
AU  - Lee, JQ
AU  - Wang, ST
AU  - Lees, N
AU  - Al-Mulla, F
AU  - Muller, O
AU  - Pauly, M
AU  - Pricolo, V
AU  - Russo, A
AU  - Troungos, C
AU  - Urosevic, N
AU  - Ward, R
PY  - 2003
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2631
T2  - Gut: An International Journal of Gastroenterology and Hepatology
T1  - Mutant K-ras2 in serum
VL  - 52
IS  - 6
SP  - 915
EP  - 916
DO  - 10.1136/gut.52.6.915-a
ER  - 

@article{
author = "Andreyev, HJN and Benamouzig, R and Beranek, M and Clarke, P and Cunningham, D and Norman, AR and Giaretti, W and de Goeij, AFPM and Iacopetta, BJ and Jullian, E and Krtolica-Žikić, Koviljka and Lee, JQ and Wang, ST and Lees, N and Al-Mulla, F and Muller, O and Pauly, M and Pricolo, V and Russo, A and Troungos, C and Urosevic, N and Ward, R",
year = "2003",
journal = "Gut: An International Journal of Gastroenterology and Hepatology",
title = "Mutant K-ras2 in serum",
volume = "52",
number = "6",
pages = "915-916",
doi = "10.1136/gut.52.6.915-a"
}

Andreyev, H., Benamouzig, R., Beranek, M., Clarke, P., Cunningham, D., Norman, A., Giaretti, W., de Goeij, A., Iacopetta, B., Jullian, E., Krtolica-Žikić, K., Lee, J., Wang, S., Lees, N., Al-Mulla, F., Muller, O., Pauly, M., Pricolo, V., Russo, A., Troungos, C., Urosevic, N.,& Ward, R.. (2003). Mutant K-ras2 in serum. in Gut: An International Journal of Gastroenterology and Hepatology, 52(6), 915-916.
https://doi.org/10.1136/gut.52.6.915-a

Andreyev H, Benamouzig R, Beranek M, Clarke P, Cunningham D, Norman A, Giaretti W, de Goeij A, Iacopetta B, Jullian E, Krtolica-Žikić K, Lee J, Wang S, Lees N, Al-Mulla F, Muller O, Pauly M, Pricolo V, Russo A, Troungos C, Urosevic N, Ward R. Mutant K-ras2 in serum. in Gut: An International Journal of Gastroenterology and Hepatology. 2003;52(6):915-916.
doi:10.1136/gut.52.6.915-a .

Andreyev, HJN, Benamouzig, R, Beranek, M, Clarke, P, Cunningham, D, Norman, AR, Giaretti, W, de Goeij, AFPM, Iacopetta, BJ, Jullian, E, Krtolica-Žikić, Koviljka, Lee, JQ, Wang, ST, Lees, N, Al-Mulla, F, Muller, O, Pauly, M, Pricolo, V, Russo, A, Troungos, C, Urosevic, N, Ward, R, "Mutant K-ras2 in serum" in Gut: An International Journal of Gastroenterology and Hepatology, 52, no. 6 (2003):915-916,
https://doi.org/10.1136/gut.52.6.915-a . .

TY  - JOUR
AU  - Trutic, N
AU  - Magic, Z
AU  - Urosevic, N
AU  - Krtolica-Žikić, Koviljka
PY  - 2002
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2577
AB  - We studied the effect of total body X-irradiation and partial hepatectomy on the acute phase protein gene expression in rat liver. Male rats of AO strain were irradiated with high X-ray doses, without any visible tissue damage. In contrast, partial hepatectomy consisted of surgical removal of 40% liver tissue. The changes in liver mRNA concentrations for positive acute-phase reactants including cysteine protease inhibitor, alpha(1)-acid glycoprotein, fibrinogen and haptoglobin, and albumin as a negative reactant were monitored by Northern blot and slot-blot hybridizations using corresponding [P-32]dCTP labeled cDNA probes. While in the first 24 h after the partial hepatectomy, liver mRNA levels for the positive acute-phase reactants increased, briefly followed by an immediate decrease, the duration and timing of the acute-phase responses to the whole body X-irradiation were slightly different and lasted for as long as 72 h. Although both treatments induced the mRNA expression of acute-phase reactants in rat liver, the observed variations in the duration and intensity of the changes in mRNA levels for the acute-phase proteins in these two types of tissue damage suggest the involvement of specific mechanisms in a fine tuning of the non-specific acute-phase responses to meet the unique requirements of the particular injury. (C) 2002 Elsevier Science Inc. All rights reserved.
T2  - Comparative Biochemistry and Physiology. C: Toxicology and Pharmacology
T1  - Acute-phase protein gene expression in rat liver following whole body X-irradiation or partial hepatectomy
VL  - 133
IS  - 3
SP  - 461
EP  - 470
DO  - 10.1016/S1532-0456(02)00174-6
ER  - 

@article{
author = "Trutic, N and Magic, Z and Urosevic, N and Krtolica-Žikić, Koviljka",
year = "2002",
abstract = "We studied the effect of total body X-irradiation and partial hepatectomy on the acute phase protein gene expression in rat liver. Male rats of AO strain were irradiated with high X-ray doses, without any visible tissue damage. In contrast, partial hepatectomy consisted of surgical removal of 40% liver tissue. The changes in liver mRNA concentrations for positive acute-phase reactants including cysteine protease inhibitor, alpha(1)-acid glycoprotein, fibrinogen and haptoglobin, and albumin as a negative reactant were monitored by Northern blot and slot-blot hybridizations using corresponding [P-32]dCTP labeled cDNA probes. While in the first 24 h after the partial hepatectomy, liver mRNA levels for the positive acute-phase reactants increased, briefly followed by an immediate decrease, the duration and timing of the acute-phase responses to the whole body X-irradiation were slightly different and lasted for as long as 72 h. Although both treatments induced the mRNA expression of acute-phase reactants in rat liver, the observed variations in the duration and intensity of the changes in mRNA levels for the acute-phase proteins in these two types of tissue damage suggest the involvement of specific mechanisms in a fine tuning of the non-specific acute-phase responses to meet the unique requirements of the particular injury. (C) 2002 Elsevier Science Inc. All rights reserved.",
journal = "Comparative Biochemistry and Physiology. C: Toxicology and Pharmacology",
title = "Acute-phase protein gene expression in rat liver following whole body X-irradiation or partial hepatectomy",
volume = "133",
number = "3",
pages = "461-470",
doi = "10.1016/S1532-0456(02)00174-6"
}

Trutic, N., Magic, Z., Urosevic, N.,& Krtolica-Žikić, K.. (2002). Acute-phase protein gene expression in rat liver following whole body X-irradiation or partial hepatectomy. in Comparative Biochemistry and Physiology. C: Toxicology and Pharmacology, 133(3), 461-470.
https://doi.org/10.1016/S1532-0456(02)00174-6

Trutic N, Magic Z, Urosevic N, Krtolica-Žikić K. Acute-phase protein gene expression in rat liver following whole body X-irradiation or partial hepatectomy. in Comparative Biochemistry and Physiology. C: Toxicology and Pharmacology. 2002;133(3):461-470.
doi:10.1016/S1532-0456(02)00174-6 .

Trutic, N, Magic, Z, Urosevic, N, Krtolica-Žikić, Koviljka, "Acute-phase protein gene expression in rat liver following whole body X-irradiation or partial hepatectomy" in Comparative Biochemistry and Physiology. C: Toxicology and Pharmacology, 133, no. 3 (2002):461-470,
https://doi.org/10.1016/S1532-0456(02)00174-6 . .

TY  - JOUR
AU  - Stamenković, Gorana
AU  - Guduric, J
AU  - Veličković, Zlate S.
AU  - Skerl, Vesna
AU  - Krtolica-Žikić, Koviljka
AU  - Velikovic, E
AU  - Dimitrijević, Bogomir B.
PY  - 2001
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2483
AB  - Single-strand conformation polymorphism (SSCP) and low-stringency single specific primer (LSSP)-PCR in hepatitis C virus (HCV) genotyping were examined for informativeness and reliability. The analysis of HCV isolates included seven type 1 isolates, two type 2 isolates, and two type 3 isolates. We also analyzed five isolates that presented as mixed infections determined by type-specific PCR. Among mixed isolates, one isolate was 1a/1b and four isolates were 1b/3a. SSCP and LSSP-PCR were applied to the analysis of 5 non-coding region of HCV (-289 to -5) that contains genotype-specific sequences. Direct cycle sequencing of this region determined sequence divergences that define genotype and sequence alterations within the same genotype. Optimized conditions for the SSCP analysis clearly distinguished between genotypes 1, 2 and 3. In addition, the SSCP analysis detected sequence variants within the same genotype. However, the SSCP analysis and DNA sequencing did not confirm the presence of mixed infections. LSSP analysis, not previously employed in HCV genotyping, enabled clear distinction between genotypes 1, 2 and 3, however, this method did not differentiate between sequence variants within a genotype. Importantly, the LSSP profile demonstrated distinction between mixed infection isolates.
T2  - Clinical Chemistry and Laboratory Medicine
T1  - Analysis of 5 non-coding region in hepatitis C virus by single-strand conformation polymorphism and low-stringency single specific primer PCR
VL  - 39
IS  - 10
SP  - 948
EP  - 952
DO  - 10.1515/CCLM.2001.152
ER  - 

@article{
author = "Stamenković, Gorana and Guduric, J and Veličković, Zlate S. and Skerl, Vesna and Krtolica-Žikić, Koviljka and Velikovic, E and Dimitrijević, Bogomir B.",
year = "2001",
abstract = "Single-strand conformation polymorphism (SSCP) and low-stringency single specific primer (LSSP)-PCR in hepatitis C virus (HCV) genotyping were examined for informativeness and reliability. The analysis of HCV isolates included seven type 1 isolates, two type 2 isolates, and two type 3 isolates. We also analyzed five isolates that presented as mixed infections determined by type-specific PCR. Among mixed isolates, one isolate was 1a/1b and four isolates were 1b/3a. SSCP and LSSP-PCR were applied to the analysis of 5 non-coding region of HCV (-289 to -5) that contains genotype-specific sequences. Direct cycle sequencing of this region determined sequence divergences that define genotype and sequence alterations within the same genotype. Optimized conditions for the SSCP analysis clearly distinguished between genotypes 1, 2 and 3. In addition, the SSCP analysis detected sequence variants within the same genotype. However, the SSCP analysis and DNA sequencing did not confirm the presence of mixed infections. LSSP analysis, not previously employed in HCV genotyping, enabled clear distinction between genotypes 1, 2 and 3, however, this method did not differentiate between sequence variants within a genotype. Importantly, the LSSP profile demonstrated distinction between mixed infection isolates.",
journal = "Clinical Chemistry and Laboratory Medicine",
title = "Analysis of 5 non-coding region in hepatitis C virus by single-strand conformation polymorphism and low-stringency single specific primer PCR",
volume = "39",
number = "10",
pages = "948-952",
doi = "10.1515/CCLM.2001.152"
}

Stamenković, G., Guduric, J., Veličković, Z. S., Skerl, V., Krtolica-Žikić, K., Velikovic, E.,& Dimitrijević, B. B.. (2001). Analysis of 5 non-coding region in hepatitis C virus by single-strand conformation polymorphism and low-stringency single specific primer PCR. in Clinical Chemistry and Laboratory Medicine, 39(10), 948-952.
https://doi.org/10.1515/CCLM.2001.152

Stamenković G, Guduric J, Veličković ZS, Skerl V, Krtolica-Žikić K, Velikovic E, Dimitrijević BB. Analysis of 5 non-coding region in hepatitis C virus by single-strand conformation polymorphism and low-stringency single specific primer PCR. in Clinical Chemistry and Laboratory Medicine. 2001;39(10):948-952.
doi:10.1515/CCLM.2001.152 .

Stamenković, Gorana, Guduric, J, Veličković, Zlate S., Skerl, Vesna, Krtolica-Žikić, Koviljka, Velikovic, E, Dimitrijević, Bogomir B., "Analysis of 5 non-coding region in hepatitis C virus by single-strand conformation polymorphism and low-stringency single specific primer PCR" in Clinical Chemistry and Laboratory Medicine, 39, no. 10 (2001):948-952,
https://doi.org/10.1515/CCLM.2001.152 . .

TY  - JOUR
AU  - Andreyev, HJN
AU  - Norman, AR
AU  - Cunningham, D
AU  - Oates, J
AU  - Dix, BR
AU  - Iacopetta, BJ
AU  - Young, J
AU  - Walsh, T
AU  - Ward, R
AU  - Hawkins, N
AU  - Beranek, M
AU  - Jandik, P
AU  - Benamouzig, R
AU  - Jullian, E
AU  - Laurent-Puig, P
AU  - Olschwang, S
AU  - Muller, O
AU  - Hoffmann, I
AU  - Rabes, HM
AU  - Zietz, C
AU  - Troungos, C
AU  - Valavanis, C
AU  - Yuen, ST
AU  - Ho, JWC
AU  - Croke, CT
AU  - O'Donoghue, DP
AU  - Giaretti, W
AU  - Rapallo, A
AU  - Russo, A
AU  - Bazan, V
AU  - Tanaka, M
AU  - Omura, K
AU  - Azuma, T
AU  - Ohkusa, T
AU  - Fujimori, T
AU  - Ono, Y
AU  - Pauly, M
AU  - Faber, C
AU  - Glaesener, R
AU  - de Goeij, AFPM
AU  - Arends, JW
AU  - Andersen, SN
AU  - Lovig, T
AU  - Breivik, J
AU  - Gaudernack, G
AU  - Clausen, OPF
AU  - De Angelis, P
AU  - Meling, GI
AU  - Rognum, TO
AU  - Smith, R
AU  - Goh, HS
AU  - Font, A
AU  - Rosell, R
AU  - Sun, XF
AU  - Zhang, H
AU  - Benhattar, J
AU  - Losi, L
AU  - Lee, JQ
AU  - Wang, ST
AU  - Clarke, PA
AU  - Bell, S
AU  - Quirke, P
AU  - Bubb, VJ
AU  - Piris, J
AU  - Cruickshank, NR
AU  - Morton, D
AU  - Fox, JC
AU  - Al-Mulla, F
AU  - Lees, N
AU  - Hall, CN
AU  - Snary, D
AU  - Wilkinson, K
AU  - Dillon, D
AU  - Costa, J
AU  - Pricolo, VE
AU  - Finkelstein, SD
AU  - Thebo, JS
AU  - Senagore, AJ
AU  - Halter, SA
AU  - Wadler, S
AU  - Malik, S
AU  - Krtolica-Žikić, Koviljka
AU  - Urosevic, N
PY  - 2001
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2458
AB  - Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes C cancers (failure-free survival. P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer. (C) 2001 Cancer Research Campaign.
T2  - British Journal of Cancer
T1  - Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study
VL  - 85
IS  - 5
SP  - 692
EP  - 696
DO  - 10.1054/bjoc.2001.1964
ER  - 

@article{
author = "Andreyev, HJN and Norman, AR and Cunningham, D and Oates, J and Dix, BR and Iacopetta, BJ and Young, J and Walsh, T and Ward, R and Hawkins, N and Beranek, M and Jandik, P and Benamouzig, R and Jullian, E and Laurent-Puig, P and Olschwang, S and Muller, O and Hoffmann, I and Rabes, HM and Zietz, C and Troungos, C and Valavanis, C and Yuen, ST and Ho, JWC and Croke, CT and O'Donoghue, DP and Giaretti, W and Rapallo, A and Russo, A and Bazan, V and Tanaka, M and Omura, K and Azuma, T and Ohkusa, T and Fujimori, T and Ono, Y and Pauly, M and Faber, C and Glaesener, R and de Goeij, AFPM and Arends, JW and Andersen, SN and Lovig, T and Breivik, J and Gaudernack, G and Clausen, OPF and De Angelis, P and Meling, GI and Rognum, TO and Smith, R and Goh, HS and Font, A and Rosell, R and Sun, XF and Zhang, H and Benhattar, J and Losi, L and Lee, JQ and Wang, ST and Clarke, PA and Bell, S and Quirke, P and Bubb, VJ and Piris, J and Cruickshank, NR and Morton, D and Fox, JC and Al-Mulla, F and Lees, N and Hall, CN and Snary, D and Wilkinson, K and Dillon, D and Costa, J and Pricolo, VE and Finkelstein, SD and Thebo, JS and Senagore, AJ and Halter, SA and Wadler, S and Malik, S and Krtolica-Žikić, Koviljka and Urosevic, N",
year = "2001",
abstract = "Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a greater impact on outcome in Dukes C cancers (failure-free survival. P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes B tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12 glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients with advanced colorectal cancer. (C) 2001 Cancer Research Campaign.",
journal = "British Journal of Cancer",
title = "Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study",
volume = "85",
number = "5",
pages = "692-696",
doi = "10.1054/bjoc.2001.1964"
}

Andreyev, H., Norman, A., Cunningham, D., Oates, J., Dix, B., Iacopetta, B., Young, J., Walsh, T., Ward, R., Hawkins, N., Beranek, M., Jandik, P., Benamouzig, R., Jullian, E., Laurent-Puig, P., Olschwang, S., Muller, O., Hoffmann, I., Rabes, H., Zietz, C., Troungos, C., Valavanis, C., Yuen, S., Ho, J., Croke, C., O'Donoghue, D., Giaretti, W., Rapallo, A., Russo, A., Bazan, V., Tanaka, M., Omura, K., Azuma, T., Ohkusa, T., Fujimori, T., Ono, Y., Pauly, M., Faber, C., Glaesener, R., de Goeij, A., Arends, J., Andersen, S., Lovig, T., Breivik, J., Gaudernack, G., Clausen, O., De Angelis, P., Meling, G., Rognum, T., Smith, R., Goh, H., Font, A., Rosell, R., Sun, X., Zhang, H., Benhattar, J., Losi, L., Lee, J., Wang, S., Clarke, P., Bell, S., Quirke, P., Bubb, V., Piris, J., Cruickshank, N., Morton, D., Fox, J., Al-Mulla, F., Lees, N., Hall, C., Snary, D., Wilkinson, K., Dillon, D., Costa, J., Pricolo, V., Finkelstein, S., Thebo, J., Senagore, A., Halter, S., Wadler, S., Malik, S., Krtolica-Žikić, K.,& Urosevic, N.. (2001). Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study. in British Journal of Cancer, 85(5), 692-696.
https://doi.org/10.1054/bjoc.2001.1964

Andreyev H, Norman A, Cunningham D, Oates J, Dix B, Iacopetta B, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes H, Zietz C, Troungos C, Valavanis C, Yuen S, Ho J, Croke C, O'Donoghue D, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij A, Arends J, Andersen S, Lovig T, Breivik J, Gaudernack G, Clausen O, De Angelis P, Meling G, Rognum T, Smith R, Goh H, Font A, Rosell R, Sun X, Zhang H, Benhattar J, Losi L, Lee J, Wang S, Clarke P, Bell S, Quirke P, Bubb V, Piris J, Cruickshank N, Morton D, Fox J, Al-Mulla F, Lees N, Hall C, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo V, Finkelstein S, Thebo J, Senagore A, Halter S, Wadler S, Malik S, Krtolica-Žikić K, Urosevic N. Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study. in British Journal of Cancer. 2001;85(5):692-696.
doi:10.1054/bjoc.2001.1964 .

Andreyev, HJN, Norman, AR, Cunningham, D, Oates, J, Dix, BR, Iacopetta, BJ, Young, J, Walsh, T, Ward, R, Hawkins, N, Beranek, M, Jandik, P, Benamouzig, R, Jullian, E, Laurent-Puig, P, Olschwang, S, Muller, O, Hoffmann, I, Rabes, HM, Zietz, C, Troungos, C, Valavanis, C, Yuen, ST, Ho, JWC, Croke, CT, O'Donoghue, DP, Giaretti, W, Rapallo, A, Russo, A, Bazan, V, Tanaka, M, Omura, K, Azuma, T, Ohkusa, T, Fujimori, T, Ono, Y, Pauly, M, Faber, C, Glaesener, R, de Goeij, AFPM, Arends, JW, Andersen, SN, Lovig, T, Breivik, J, Gaudernack, G, Clausen, OPF, De Angelis, P, Meling, GI, Rognum, TO, Smith, R, Goh, HS, Font, A, Rosell, R, Sun, XF, Zhang, H, Benhattar, J, Losi, L, Lee, JQ, Wang, ST, Clarke, PA, Bell, S, Quirke, P, Bubb, VJ, Piris, J, Cruickshank, NR, Morton, D, Fox, JC, Al-Mulla, F, Lees, N, Hall, CN, Snary, D, Wilkinson, K, Dillon, D, Costa, J, Pricolo, VE, Finkelstein, SD, Thebo, JS, Senagore, AJ, Halter, SA, Wadler, S, Malik, S, Krtolica-Žikić, Koviljka, Urosevic, N, "Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study" in British Journal of Cancer, 85, no. 5 (2001):692-696,
https://doi.org/10.1054/bjoc.2001.1964 . .

TY  - JOUR
AU  - Stamenković, Gorana
AU  - Zerjav, S
AU  - Velickovic, ZM
AU  - Krtolica-Žikić, Koviljka
AU  - Samardzija, VL
AU  - Jemuovic, L
AU  - Nozic, D
AU  - Dimitrijević, Bogomir B.
PY  - 2000
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2424
AB  - Blood samples from 190 patients that were anti-hepatitis C virus (HCV) positive were genotyped and 165 were found to contain HCV-RNA. Genotyping was performed by PCR based on type-specific primers (117 isolates) and LiPA test (48 isolates) and verifying by sequencing. In Serbia, the most frequent genotype was 1b (49.1%), followed by genotype 3 (21.2%) and genotype 1a (8.5%). The frequency of genotypes 2 and 4 was below 5% and mixed infections were encountered in 9.1% of cases. Distribution of genotypes was monitored in different risk groups: intravenous drug abusers, patients under blood transfusion, patients with previous history of surgery, patients undergoing hemodialysis and those with unknown risk factors. Genotype distribution is essentially the same in all the groups, except for the patients undergoing hemodialysis and those with previous history of surgery where significant difference exists compared with the group with unknown route of transmission (p LT 0.001 and p LT 0.05, respectively). There exists significant age-dependent genotype 3 distribution in Serbian population (p LT 0.01).
T2  - European Journal of Epidemiology
T1  - Distribution of HCV genotypes among risk groups in Serbia
VL  - 16
IS  - 10
SP  - 949
EP  - 954
DO  - 10.1023/A:1011060505152
ER  - 

@article{
author = "Stamenković, Gorana and Zerjav, S and Velickovic, ZM and Krtolica-Žikić, Koviljka and Samardzija, VL and Jemuovic, L and Nozic, D and Dimitrijević, Bogomir B.",
year = "2000",
abstract = "Blood samples from 190 patients that were anti-hepatitis C virus (HCV) positive were genotyped and 165 were found to contain HCV-RNA. Genotyping was performed by PCR based on type-specific primers (117 isolates) and LiPA test (48 isolates) and verifying by sequencing. In Serbia, the most frequent genotype was 1b (49.1%), followed by genotype 3 (21.2%) and genotype 1a (8.5%). The frequency of genotypes 2 and 4 was below 5% and mixed infections were encountered in 9.1% of cases. Distribution of genotypes was monitored in different risk groups: intravenous drug abusers, patients under blood transfusion, patients with previous history of surgery, patients undergoing hemodialysis and those with unknown risk factors. Genotype distribution is essentially the same in all the groups, except for the patients undergoing hemodialysis and those with previous history of surgery where significant difference exists compared with the group with unknown route of transmission (p LT 0.001 and p LT 0.05, respectively). There exists significant age-dependent genotype 3 distribution in Serbian population (p LT 0.01).",
journal = "European Journal of Epidemiology",
title = "Distribution of HCV genotypes among risk groups in Serbia",
volume = "16",
number = "10",
pages = "949-954",
doi = "10.1023/A:1011060505152"
}

Stamenković, G., Zerjav, S., Velickovic, Z., Krtolica-Žikić, K., Samardzija, V., Jemuovic, L., Nozic, D.,& Dimitrijević, B. B.. (2000). Distribution of HCV genotypes among risk groups in Serbia. in European Journal of Epidemiology, 16(10), 949-954.
https://doi.org/10.1023/A:1011060505152

Stamenković G, Zerjav S, Velickovic Z, Krtolica-Žikić K, Samardzija V, Jemuovic L, Nozic D, Dimitrijević BB. Distribution of HCV genotypes among risk groups in Serbia. in European Journal of Epidemiology. 2000;16(10):949-954.
doi:10.1023/A:1011060505152 .

Stamenković, Gorana, Zerjav, S, Velickovic, ZM, Krtolica-Žikić, Koviljka, Samardzija, VL, Jemuovic, L, Nozic, D, Dimitrijević, Bogomir B., "Distribution of HCV genotypes among risk groups in Serbia" in European Journal of Epidemiology, 16, no. 10 (2000):949-954,
https://doi.org/10.1023/A:1011060505152 . .

TY  - CONF
AU  - Todoric, B
AU  - Malesevic, M
AU  - Stamatovic, D
AU  - Magic, Z
AU  - Balint, B
AU  - Krtolica-Žikić, Koviljka
PY  - 1999
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2236
C3  - Bone Marrow Transplantation
T1  - Minimal residual, disease in CML patients submitted to stem cell transplantation
VL  - 23
SP  - S151
EP  - S151
UR  - https://hdl.handle.net/21.15107/rcub_vinar_2236
ER  - 

@conference{
author = "Todoric, B and Malesevic, M and Stamatovic, D and Magic, Z and Balint, B and Krtolica-Žikić, Koviljka",
year = "1999",
journal = "Bone Marrow Transplantation",
title = "Minimal residual, disease in CML patients submitted to stem cell transplantation",
volume = "23",
pages = "S151-S151",
url = "https://hdl.handle.net/21.15107/rcub_vinar_2236"
}

Todoric, B., Malesevic, M., Stamatovic, D., Magic, Z., Balint, B.,& Krtolica-Žikić, K.. (1999). Minimal residual, disease in CML patients submitted to stem cell transplantation. in Bone Marrow Transplantation, 23, S151-S151.
https://hdl.handle.net/21.15107/rcub_vinar_2236

Todoric B, Malesevic M, Stamatovic D, Magic Z, Balint B, Krtolica-Žikić K. Minimal residual, disease in CML patients submitted to stem cell transplantation. in Bone Marrow Transplantation. 1999;23:S151-S151.
https://hdl.handle.net/21.15107/rcub_vinar_2236 .

Todoric, B, Malesevic, M, Stamatovic, D, Magic, Z, Balint, B, Krtolica-Žikić, Koviljka, "Minimal residual, disease in CML patients submitted to stem cell transplantation" in Bone Marrow Transplantation, 23 (1999):S151-S151,
https://hdl.handle.net/21.15107/rcub_vinar_2236 .